- Home
- DOYU vs TVRD Comparison
DOYU vs TVRD Comparison
Compare DOYU & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | TVRD |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.6M | 246.5M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | DOYU | TVRD |
|---|---|---|
| Price | $7.07 | $4.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.00 | ★ $51.67 |
| AVG Volume (30 Days) | 31.9K | ★ 123.7K |
| Earning Date | 11-20-2025 | 11-13-2025 |
| Dividend Yield | ★ 141.29% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $566,928,371.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $3.74 |
| 52 Week High | $16.99 | $43.65 |
Technical Indicators
Market Signals| Indicator | DOYU | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 34.35 |
| Support Level | $6.58 | $4.05 |
| Resistance Level | $7.15 | $4.71 |
| Average True Range (ATR) | 0.23 | 0.27 |
| MACD | 0.01 | 0.55 |
| Stochastic Oscillator | 73.85 | 73.20 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.